Oslo University Hospital, Rikshospitalet

Oslo 0424

2 studies enrolling now · 10 studies all time

What they study most

AL Amyloidosis, Acute Myocardial Infarction, Congenital Heart Disease, Dilated Cardiomyopathy, Hematopoietic Stem Cells, Idiopathic Pulmonary Fibrosis, Lamin A/C Gene Mutation, Neuroendocrine Tumour of the Lung, Neuroendocrine Tumours, Paroxysmal Nocturnal Hemoglobinuria, Small Intestinal NET, Stroke, Acute

Studies at this site

• MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) — Recruiting now
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction — Enrolling by invitation
• A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis — Running, not enrolling
• Open-Label Surufatinib in European Patients With NET — Stopped early
• Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis — Completed
• Assessment of Patterns of Patient Reported Outcomes in Adults With Congenital Heart Disease - International Study II — Completed
• A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation — Stopped early
• Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation — Completed
• A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH — Completed
• A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis — Stopped early